Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in this application:

Listing of Claims:

Claim 1 (Original): A composition comprising one or more salts of tiotropium **1** and one or more pharmacologically acceptable salts of a compound of formula **2'**



2'

wherein

R^1 and R^2 which may be identical or different denote hydrogen or C_1-C_4-alkyl;

R^3 and R^4 which may be identical or different denote hydrogen, C_1-C_4-alkyl, -O-C_1-C_4-alkyl, - C_1-C_4-alkylene-O-C_1-C_4-alkyl or

R^3 and R^4 together denote one of the bridging groups

- C_1-C_4-alkylene- or -O-C_1-C_4-alkylene-O-; together with a pharmaceutically acceptable carrier.

Claim 2 (Original): The composition according to claim 1 wherein the one or more salts of tiotropium **1** is in the form of the chloride, bromide, iodide, methanesulphonate, paratoluene sulphonate or methyl sulphate.

Claim 3 (Original): The composition according to claim 1 wherein, for the compound of formula **2'**,

R^1 and R^2 which may be identical or different denote hydrogen, methyl or ethyl;

R^3 and R^4 which may be identical or different denote hydrogen, methyl, ethyl, propyl, butyl, methoxy, ethoxy, methyoxymethyl, or methoxyethyl, or

R^3 and R^4 together denote one of the bridging groups

propylene, butylene, -O-ethylene-O- or -O-propylene-O-.

Claim 4 (Original): The composition according to claim 1 wherein the one or more salts of tiotropium **1** and the one or more pharmacologically acceptable salts of compound **2'** are either present together in a single preparation or are contained in two separate preparations.

Claim 5 (Previously presented): The composition according to claim 4 wherein the weight ratios of **1** to **2'** are in the range from 1:300 to 30:1.

Claim 6 (Previously presented): The composition according to claim 4 wherein a single application corresponds to a dosage of the combination of compounds **1** and **2'** of 0.01 to 10000µg.

Claim 7 (Original): The composition according to claim 4 that it is in the form of a formulation suitable for inhalation.

Claim 8 (Original): The composition according to claim 7 wherein the form is selected from the group consisting of inhalable powders, propellant-containing metering aerosols and propellant-free inhalable solutions or suspensions.

Claim 9 (Currently amended): The composition according to claim 8 comprising an inhalable powder which contains **1** and **2'** in admixture with suitable physiologically acceptable excipients selected from the group consisting of monosaccharides, disaccharides, oligo- and polysaccharides, polyalcohols, salts, and mixtures of these excipients.

Claim 10 (Original): The composition according to claim 9 wherein the excipient has a maximum average particle size of 250µm.

Claim 11 (Original): The composition according to claim 9 contained in a capsule.

Claim 12 (Previously presented): The composition according to claim 8 in the form of an inhalable powder consisting essentially of compounds **1** and **2'**.

Claim 13 (Previously presented): The composition according to claim 8 in the form of a propellant-containing inhalable aerosol comprising compounds **1** and **2'** in dissolved or dispersed form.

Claim 14 (Original): The composition according to claim 8 in the form of a propellant-free inhalable solution or suspension comprising water, ethanol or a mixture of water and ethanol as a solvent.

Claim 15 (Previously presented): A method for treating inflammatory or obstructive diseases of the respiratory tract comprising the administration to a patient of a therapeutically effective amount of the composition according to claim 1.